Vapotherm announces publication of heart failure study

Vapotherm announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation, or NiPPV, in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure, or ADHF. More than one million patients with ADHF as a primary diagnosis are admitted to U.S. hospitals each year. The ADHF patient subgroup is from a larger multi-center trial that compares the efficacy of NiPPV and High Velocity Nasal Insufflation, or HVNI, in treating adults in undifferentiated respiratory distress presenting in the Emergency Department, or ED, that found HVNI non-inferior to NiPPV. This ADHF subgroup analysis, which examined the 42 patients that constituted the subset of enrolled patients with an ADHF discharge diagnosis, determined that the primary clinical outcomes between Hi-VNI and NiPPV are also comparable for the subgroup. Secondary outcomes of the original study included findings that Vapotherm’s Hi-VNI Technology was superior or equivalent to NiPPV in the physician perception of patient comfort and tolerance, and the clinical use of the technology.

https://thefly.com/landingPageNews.php?id=2884195